ストックスクリーナーアプリを入手
1.115
4.67%
0.045
Cognition Therapeutics Inc (CGTX) 最新ニュース
Price to sales forward of Cognition Therapeutics, Inc. – NASDAQ:CGTX - TradingView
Cognition Therapeutics, Inc. Financial Disclosures & SEC Filings - TradingView
H.C. Wainwright reiterates Cognition Therapeutics stock rating on FDA alignment - Investing.com South Africa
Cognition Therapeutics Slides Amid Sector Weakness; Key Support Levels in FocusTrading Ideas - dars.gov.et
We're Keeping An Eye On Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate - Moomoo
Cognition Therapeutics, Inc.(NasdaqCM:CGTX) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Cognition Therapeutics, Inc.(NasdaqCM: CGTX) added to Russell 3000E Growth Benchmark - marketscreener.com
Cognition Therapeutics, Inc.(NasdaqCM: CGTX) added to Russell Microcap Index - marketscreener.com
Cognition Therapeutics gets positive FDA feedback over phase 3 study of DLB psychosis – but CGTX stock just crashed 33% - MSN
Cognition Therapeutics, Inc.(NasdaqCM: CGTX) added to Russell 3000E Index - marketscreener.com
Cognition, FDA agree on late-stage trial for dementia therapy - MSN
symbol__ Stock Quote Price and Forecast - CNN
Cognition Therapeutics: Clearer FDA Path, But Potential Dilution Risks Remain - Seeking Alpha
Cognition Therapeutics, Inc. Actuals & Estimates (NASDAQ:CGTX) - TradingView
H.C. Wainwright Maintains Cognition Therapeutics(CGTX.US) With Buy Rating, Maintains Target Price $3 - Moomoo
CGTX Forecast — Price Target — Prediction for 2027 - TradingView
Cognition Therapeutics | 10-K: FY2025 Annual Report - Moomoo
FDA says DLB psychosis could be approvable in Cognition trial plan - Stock Titan
Cognition Therapeutics receives FDA alignment on Phase 3 trial of zervimesine for DLB psychosis - grafa.com
Cognition Therapeutics Gets Positive FDA Feedback Over Phase 3 Study Of DLB Psychosis – But CGTX Stock Just Crashed 33% - TradingView
Cognition Therapeutics Secures FDA Alignment for Pivotal Phase 3 Trial of Zervimesine in DLB Psychosis, Targeting First Durable Treatment Option 1 – Minichart - Minichart
Cognition Therapeutics Advances After FDA Supports Key Elements of Pivotal Trial Plan (CGTX) - Yahoo Finance
Cognition Therapeutics Agrees With FDA on Phase 3 Trial Framework for Psychosis Treatment - marketscreener.com
Cognition Therapeutics stock rises on FDA trial alignment By Investing.com - Investing.com Canada
Cognition Therapeutics aligned with FDA on pivotal Phase 3 design for zervimesine in DLB psychosis - TradingView
Cognition Therapeutics Secures FDA Alignment for Phase 3 Zervimesine Trial in DLB Psychosis - Quiver Quantitative
Cognition Therapeutics (NASDAQ: CGTX) wins FDA alignment on pivotal DLB psychosis study for zervimesine - Stock Titan
Cognition Therapeutics Aligns on Key Aspects of Pivotal - GlobeNewswire
Form DEF 14A Cognition Therapeutics Inc For: 23 June By Investing.com - Investing.com India
Form 4 Cognition Therapeutics Inc For: 22 June By Investing.com - Investing.com South Africa
Cognition Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Khattar Jack A. - Moomoo
Director at Cognition Therapeutics (CGTX) awarded 25,000 RSUs - Stock Titan
Director at Cognition Therapeutics (CGTX) receives 25,000 RSUs and holds 73,500 shares - Stock Titan
RSU grant lifts Cognition Therapeutics (CGTX) director Peggy Wallace’s holdings - Stock Titan
Cognition Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Wallace Peggy - Moomoo
Director at Cognition Therapeutics (CGTX) granted 25,000 RSUs - Stock Titan
[Form 4] COGNITION THERAPEUTICS INC Insider Trading Activity - Stock Titan
H.C. Wainwright reiterates Cognition Therapeutics stock rating on patent news By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Cognition Therapeutics stock rating on patent news - Investing.com
Cognition Therapeutics Shareholders Elect Directors, Ratify Auditor - The Globe and Mail
Cognition Therapeutics Advances Zervimesine Toward Phase 3 DLB Trial - TipRanks
Cognition Therapeutics elects directors and ratifies auditor at annual meeting - Investing.com UK
Cognition Therapeutics elects directors and ratifies auditor at annual meeting By Investing.com - Investing.com Nigeria
1.53%
3.59%
大文字化:
|
ボリューム (24 時間):